Impact of amyloid imaging on drug development in Alzheimer's disease
Impact of amyloid imaging on drug development in Alzheimer's disease
复制标题
DOI：
10.1016/j.nucmedbio.2007.06.015
复制
发表时间：
2007-10-01
影响因子：
3.1
通讯作者：
Klunk, William E.
中科院分区：
文献类型：
--
作者：
Mathis, Chester A.;Lopresti, Brian J.;Klunk, William E.
能够评估阿尔茨海默病（AD）受试者脑中体内淀粉样蛋白-β（A）含量的成像剂可能作为检测脑中A斑块的诊断剂以及帮助测试AD的淀粉样蛋白级联假说和作为评估目前正在开发和临床试验中的抗淀粉样蛋白治疗剂的功效的辅助剂是重要的。正电子发射断层扫描（PET）成像研究淀粉样蛋白沉积在人类受试者与几个A成像剂目前正在进行中。我们在2004年首次报道了碳11标记的硫磺素-T衍生物匹兹堡化合物B的PET研究，这项工作随后扩展到包括各种受试者群体，包括AD患者、轻度认知障碍患者和健康对照。量化活体人类受试者脑中局部A斑块负荷的能力提供了一种方法，开始应用该技术作为诊断剂来检测A斑块的局部浓度，并作为抗淀粉样蛋白药物试验中治疗功效的替代标记。(C)2007年爱思唯尔公司All rights reserved.
Imaging agents capable of assessing amyloid-beta (A) content in vivo in the brains of Alzheimer's disease (AD) subjects likely will be important as diagnostic agents to detect A plaques in the brain as well as to help test the amyloid cascade hypothesis of AD and as an aid to assess the efficacy of anti-amyloid therapeutics currently under development and in clinical trials. Positron emission tomography (PET) imaging studies of amyloid deposition in human subjects with several A imaging agents are currently underway. We reported the first PET studies of the carbon 11-labeled thioflavin-T derivative Pittsburgh Compound B in 2004, and this work has subsequently been extended to include a variety of subject groups, including AD patients, mild cognitive impairment patients and healthy controls. The ability to quantify regional A plaque load in the brains of living human subjects has provided a means to begin to apply this technology as a diagnostic agent to detect regional concentrations of A plaques and as a surrogate marker of therapeutic efficacy in anti-amyloid drug trials. (C) 2007 Elsevier Inc. All rights reserved.